J 2012

Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson’s disease?

BAREŠ, Martin, Irena REKTOROVÁ, Robert JECH, Kateřina FARNÍKOVÁ, Jan ROTH et. al.

Basic information

Original name

Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson’s disease?

Authors

BAREŠ, Martin (203 Czech Republic, guarantor, belonging to the institution), Irena REKTOROVÁ (203 Czech Republic, belonging to the institution), Robert JECH (203 Czech Republic), Kateřina FARNÍKOVÁ (203 Czech Republic), Jan ROTH (203 Czech Republic), Evžen RŮŽIČKA (203 Czech Republic), Petr KAŇOVSKÝ (203 Czech Republic), Ivan REKTOR (203 Czech Republic, belonging to the institution), Tomáš PAVLÍK (203 Czech Republic, belonging to the institution), Leona UHLÍŘOVÁ (203 Czech Republic) and Jaroslav VYDLÁK (203 Czech Republic)

Edition

Journal of Neural Transmission, 2012, 0300-9564

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30000 3. Medical and Health Sciences

Country of publisher

Austria

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 3.052

RIV identification code

RIV/00216224:14110/12:00059524

Organization unit

Faculty of Medicine

DOI

UT WoS

000300587900010

Keywords in English

Wearing-off; Parkinson’s disease; Levodopa; WOQ-9; Epidemiology

Tags

International impact
Změněno: 16/4/2013 16:34, Ing. Mgr. Věra Pospíšilíková

Abstract

V originále

EWO (Epidemiology of Wearing-Off symptoms among the population of Parkinson’s disease (PD) patients on L-DOPA) is a multicentric, non-interventional, epidemiological and exploratory trial, focused on patients with PD who are treated with L-DOPA. The primary objective is the estimation of wearing-off symptoms (based on WOQ-9 questionnaire and assessment by neurologists) among PD patients who are treated with L-DOPA. From September 30, 2007 to June 30, 2008 altogether 563 valid records of PD patients were collected in movement disorders centers (Level A and Level B centers). Wearing-off symptoms were observed in 66.7% of PD patients (neurologists’ assessment) and in 90.6% of PD patients (WOQ-9 questionnaire). The biggest discrepancy was found in PD patients treated with L-DOPA for 0–2 years. The probability of detecting wearing-off by the neurologists strongly correlated with the highest number of positive responses in the WOQ-9 marked by PD patients. There was significant difference in the diagnosis of wearing-off between Level A centers (77.7%) and Level B centers (62.0%). When motor and non-motor symptoms in the WOQ-9 were considered, the difference between neurologists came from the detection of non-motor symptoms (lower in the Level B centers). The neurologists’ assessment of wearing-off symptoms and PD patients’ subjective evaluation of the WOQ-9 is based on the experience of the neurologist and on the detection of the non-motor symptoms of wearing-off. Careful explanation of the WOQ-9 questionnaire and improved awareness of the non-motor symptoms of wearing-off is strongly suggested.